quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:19:00·56d
PRRelease
Atrium Therapeutics Inc. logo

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

RNA· Atrium Therapeutics Inc.
Health Care
Original source

Companies

  • RNA
    Atrium Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 11UpdateWells Fargo$25.00
  • Sep 17UpdateRoth Capital$62.00
  • Jul 10UpdateGoldman$55.00
  • Jun 24UpdateBernstein$50.00
  • Jun 17UpdateWolfe Research$55.00
  • Jun 11UpdateRaymond James$65.00

Related

  • PR1d
    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
  • INSIDER1d
    SEC Form 4 filed by Kenney Stephanie
  • INSIDER1d
    SEC Form 4 filed by Hughes Steven George
  • INSIDER1d
    SEC Form 4 filed by Winslow Brendan R.
  • INSIDER1d
    SEC Form 4 filed by Gallagher Kathleen P.
  • INSIDER1d
    SEC Form 4 filed by Hoyos Rocio Martin
  • INSIDER1d
    SEC Form 4 filed by Younis Husam
  • PR3d
    Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022